Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMX-101 (Amzeeq) in moderate-to-severe acne vulgaris
NCT02815267Phase 3Completed
- Sponsor
- Vyne Therapeutics
- Start
- May 2016
- Primary completion
- Oct 2017
- Modality
- Transdermal Patches, Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of zilxi in acne vulgaris, sponsored by Vyne Therapeutics. Started May 2016; status: completed.
02
Drugs
zilxi
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT02815267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02815267.